Search

Displaying results 4821 - 4830 of 10000 in total
  1. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. … The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  2. Drug

    VGA039

    go.drugbank.com/drugs/DB18385
    Investigational

    VGA039 is an IgG4 monoclonal antibody directed against protein S.

  3. Drug

    GB1211

    go.drugbank.com/drugs/DB17499
    Investigational

    GB1211 is an orally active galectin-3 (Gal-3) inhibitor.

  4. Drug

    RAPA-201

    go.drugbank.com/drugs/DB18446
    Investigational

    RAPA-201 is an autologous rapamycin-resistant T-cell therapy.

  5. Drug

    Givastomig

    go.drugbank.com/drugs/DB18618
    Investigational

    Givastomig is an anti-Claudin 18.2 and 4.1BB bispecific antibody.

    Synonyms: an anti-Claudin 18.2 and 4.1BB Bispecific Antibody
  6. Drug

    Clorgiline

    go.drugbank.com/drugs/DB04017
    Experimental

    An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A Inhibitors
  7. Drug

    Cytidine-5'-Monophosphate

    go.drugbank.com/drugs/DB03403
    Investigational

    A pyrimidine ribonucleoside 5'-monophosphate having cytosine as the nucleobase.

    Synonyms: pC
  8. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  9. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). … [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.

  10. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    )[L12675] with an expected completion in December 2020. … Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.